Curanex Pharmaceuticals cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 6 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2024 | Dec2024 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | -0.09M | -0.15M | -0.06M | -0.96M | -3.09M | -3.33M |
| Cash from OperationsCash from Ops. | -0.13M | -0.10M | -9.19M | -0.86M | ||
| Depreciation, Depletion & Amortization | ||||||
| Amortizatization of IntangiblesAmort. of Intangibles | 0.02M | 0.03M | ||||
| Change in Working Capital | ||||||
| Change in Account PayablesChange Payables | 0.11M | -0.11M | ||||
| Change in Accured ExpensesChange Accured Exp. | 0.00M | 0.01M | 0.01M | 0.00M | ||
| Other Working Capital ChangesOther WC Changes | 0.05M | 0.03M | ||||
| Financing Activities | ||||||
| Cash from Financing ActivitiesCash from Financing | 14.91M | |||||
| Additional items | ||||||
| Change in Cash | -0.13M | -0.10M | 5.72M | -0.86M | ||
| Free Cash FlowFCF | -0.13M | -0.10M | -9.19M | -0.86M | ||
| Net Cash FlowNCF | -0.13M | -0.10M | 5.72M | -0.86M |